Negative / Null Result ReportMedicine
Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology
Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…
View details →DOI: 10.1200/po.23.00406 Negative / Null Result ReportOpen accessMedicine
King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV
Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…
View details →DOI: 10.1111/jdv.20605 Negative / Null Result ReportMedicine
Schulte B, Mohindra N, Milhem M et al. · 2021 · British journal of cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with…
View details →DOI: 10.1038/s41416-021-01448-0 Negative / Null Result ReportOpen accessMedicine
Thavaneswaran S, Lin F, Espinoza D et al. · 2025 · NPJ precision oncology
This single-arm phase II trial (ACTRN12620000918921) evaluated the clinical activity of tremelimumab (10 mg/kg intravenously every 4 weeks for 6 cycles) in advanced cancers with a high tumour mutational burden (TMB), defined as TMB > 10…
View details →DOI: 10.1038/s41698-025-01156-5 Negative / Null Result ReportOpen accessMedicine
Hsu YC, Lin PT, Teng W et al. · 2024 · Cancers
Background The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for…
View details →DOI: 10.3390/cancers16203458 Negative / Null Result ReportMedicine
Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology
Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…
View details →DOI: 10.1007/s10147-022-02151-7 Negative / Null Result ReportMedicine
Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma
Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…
View details →DOI: 10.1080/02770903.2021.1938603 Negative / Null Result ReportOpen accessMedicine
Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders
Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…
View details →DOI: 10.1177/17562864261427169 Negative / Null Result ReportMedicine
Lumish M, Chui MH, Zhou Q et al. · 2024 · Gynecologic oncology
Objective HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but…
View details →DOI: 10.1016/j.ygyno.2023.12.028 Negative / Null Result ReportOpen accessMedicine
Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy
Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…
View details →DOI: 10.1007/s13555-026-01746-6 Negative / Null Result ReportOpen accessMedicine
Chang JY, Balch C, Oh HS · 2024 · Viruses
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or…
View details →DOI: 10.3390/v16091476 Negative / Null Result ReportMedicine
Sabha M, Siaton BC, Hochberg MC · 2020 · Expert opinion on investigational drugs
Introduction : Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all…
View details →DOI: 10.1080/13543784.2020.1842357 Negative / Null Result ReportOpen accessMedicine
Lin CL, Chen MC, Lin CY et al. · 2026 · Journal of robotic surgery
Minimally invasive total mesorectal excision (TME) for rectal cancer can be performed via transanal TME (TaTME) or robotic TME (R-TME), yet comparative evidence in predominantly non-obese Asian cohorts remains limited. We evaluated a…
View details →DOI: 10.1007/s11701-026-03241-8 Negative / Null Result ReportMedicine
Koch MW, Sage K, Kaur S et al. · 2021 · Neurology
Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.…
View details →DOI: 10.1212/wnl.0000000000011863 Negative / Null Result ReportOpen accessMedicine
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
View details →DOI: 10.1158/1078-0432.ccr-25-0618 Negative / Null Result Report
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
View details →DOI: 10.21203/rs.3.rs-268461/v1 Negative / Null Result ReportMedicine
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
View details →DOI: 10.1007/s10549-021-06292-7 Negative / Null Result ReportMedicine
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
View details →DOI: 10.1177/13524585211032803 Negative / Null Result ReportOpen accessMedicine
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
View details →DOI: 10.3389/fonc.2022.932105 Negative / Null Result ReportOpen accessMedicine
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
View details →DOI: 10.5853/jos.2025.01200 Negative / Null Result ReportOpen accessMedicine
Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy
Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…
View details →DOI: 10.1038/s41392-025-02173-3 Negative / Null Result ReportOpen accessMedicine
Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer
Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…
View details →DOI: 10.1136/jitc-2023-008409 Negative / Null Result ReportOpen accessMedicine
Pravisano F, Costa J, Marchi L et al. · 2026 · Cancers
The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB-IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant…
View details →DOI: 10.3390/cancers18111802 Negative / Null Result ReportMedicine
Agnihotri G, Lio PA · 2020 · Clinical drug investigation
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs…
View details →DOI: 10.1007/s40261-020-00905-7 Negative / Null Result ReportOpen accessMedicine
Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)
The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…
View details →DOI: 10.1016/j.breast.2023.06.007 Negative / Null Result ReportMedicine
Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer
Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…
View details →DOI: 10.1002/cncr.35151 Negative / Null Result ReportMedicine
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
View details →DOI: 10.1093/rheumatology/kead281 Negative / Null Result ReportOpen accessMedicine
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
View details →DOI: 10.1093/oncolo/oyaf162 Negative / Null Result ReportOpen accessMedicine
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
View details →DOI: 10.3389/fcvm.2025.1578159 Negative / Null Result ReportMedicine
Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
View details →DOI: 10.1016/j.euo.2025.04.026 